BlackRock Inc. Buys Shares of 26,711,079 DENTSPLY SIRONA Inc. $XRAY

BlackRock Inc. purchased a new position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 26,711,079 shares of the medical instruments supplier’s stock, valued at approximately $283,405,000. BlackRock Inc. owned 0.13% of DENTSPLY SIRONA as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Southpoint Capital Advisors LP purchased a new stake in DENTSPLY SIRONA in the first quarter worth approximately $116,000,000. AQR Capital Management LLC lifted its holdings in shares of DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares during the period. Armistice Capital LLC boosted its stake in shares of DENTSPLY SIRONA by 1,044.0% in the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after buying an additional 5,234,587 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of DENTSPLY SIRONA by 662.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock worth $58,480,000 after acquiring an additional 4,003,606 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY opened at $10.93 on Thursday. The company has a market capitalization of $2.18 billion, a P/E ratio of -3.97, a P/E/G ratio of 1.38 and a beta of 0.85. DENTSPLY SIRONA Inc. has a 1-year low of $9.40 and a 1-year high of $14.86. The firm’s 50 day simple moving average is $12.07 and its two-hundred day simple moving average is $11.77. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. The firm had revenue of $898.00 million during the quarter, compared to analysts’ expectations of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts expect that DENTSPLY SIRONA Inc. will post 1.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director Brian T. Gladden purchased 9,985 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were acquired at an average cost of $10.02 per share, with a total value of $100,049.70. Following the completion of the acquisition, the director directly owned 61,849 shares in the company, valued at $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Brian P. Mckeon acquired 10,000 shares of the stock in a transaction dated Friday, June 12th. The stock was acquired at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at approximately $101,200. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 35,160 shares of company stock worth $351,179. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on XRAY. Piper Sandler increased their target price on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. BMO Capital Markets restated a “market perform” rating and set a $13.00 price target on shares of DENTSPLY SIRONA in a research note on Friday, August 7th. Mizuho reduced their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Barrington Research set a $15.00 price objective on shares of DENTSPLY SIRONA in a report on Monday, August 10th. Finally, UBS Group cut their target price on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, DENTSPLY SIRONA presently has a consensus rating of “Hold” and a consensus price target of $13.54.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.